Femasys (FEMY) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 09, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Document Transition Report	false
Entity File Number	001-40492
Entity Registrant Name	Femasys Inc.
Entity Central Index Key	0001339005
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3713499
Entity Address, Address Line One	3950 Johns Creek Court, Suite 100
Entity Address, City or Town	Suwanee
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30024
City Area Code	770
Local Phone Number	500-3910
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	FEMY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,799,720

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 27,280,309	$ 3,322,226
Accounts receivable, net	143,459	125,790
Inventory, net	150,336	131,378
Other current assets	759,453	284,115
Total current assets	28,333,557	3,863,509
Property and equipment, at cost:
Leasehold improvements	1,155,332	1,155,332
Office equipment	99,344	64,145
Furniture and fixtures	424,947	424,947
Machinery and equipment	2,262,908	2,242,088
Construction in progress	268,226	139,150
Property and equipment, Gross	4,210,757	4,025,662
Less accumulated depreciation	(2,600,787)	(2,197,868)
Net property and equipment	1,609,970	1,827,794
Long-term assets:
Lease right-of-use assets, net	759,018	1,057,506
Intangible assets, net of accumulated amortization	33,046	65,069
Other long-term assets	428,933	792,440
Total long-term assets	1,220,997	1,915,015
Total assets	31,164,524	7,606,318
Current liabilities:
Accounts payable	436,890	674,333
Accrued expenses	597,856	1,117,601
Clinical holdback - current portion	18,947	0
Notes payable - current portion	320,866	630,010
Lease liabilities - current portion	412,911	434,072
Other - current	32,895	32,895
Total current liabilities	1,820,365	2,888,911
Long-term liabilities:
Clinical holdback - long-term portion	155,960	164,972
Note payable - long-term portion	0	182,490
Lease liabilities - long-term portion	501,912	809,092
Other - long-term	32,895	32,895
Total long-term liabilities	690,767	1,189,449
Total liabilities	2,511,132	4,078,360
Commitments and contingencies
Stockholders' equity (deficit):
Common stock, $.001 par, 200,000,000 authorized, 11,916,943 shares issued and 11,799,720 outstanding as of September 30, 2021; and 95,583,558 authorized, 1,110,347 shares issued and 993,124 outstanding as of December 31, 2020	11,916	1,110
Treasury stock, 117,223 shares	(60,000)	(60,000)
Warrants	702,492	702,492
Additional paid-in-capital	108,374,466	22,725,949
Accumulated deficit	(80,375,482)	(75,202,490)
Total stockholders' equity (deficit)	28,653,392	(51,815,728)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	31,164,524	7,606,318
Series B Preferred Stock [Member]
Redeemable convertible preferred stock:
Preferred stock	0	10,748,873
Series C Preferred Stock [Member]
Redeemable convertible preferred stock:
Preferred stock	0	44,594,813
Series A Preferred Stock [Member]
Stockholders' equity (deficit):
Preferred stock, Series A, $.001 par, none authorized, issued and outstanding as of September 30, 2021; 17,310,609 shares authorized, and 17,210,609 shares issued and outstanding as of December 31, 2020	$ 0	$ 17,211

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Stockholders' equity (deficit):
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	200,000,000	95,583,558
Common stock, issued (in shares)	11,916,943	1,110,347
Common stock, outstanding (in shares)	11,799,720	993,124
Treasury stock, shares (in shares)	117,223	117,223
Series B Preferred Stock [Member]
Redeemable convertible preferred stock:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	0	13,344,349
Preferred stock, shares issued (in shares)	0	13,344,349
Preferred stock, shares outstanding (in shares)	0	13,344,349
Series C Preferred Stock [Member]
Redeemable convertible preferred stock:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	0	42,491,484
Preferred stock, shares issued (in shares)	0	42,491,484
Preferred stock, shares outstanding (in shares)	0	42,491,484
Series A Preferred Stock [Member]
Stockholders' equity (deficit):
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	0	17,310,609
Preferred stock, shares issued (in shares)	0	17,210,609
Preferred stock, shares outstanding (in shares)	0	17,210,609

Statements of Comprehensive Los

Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statements of Comprehensive Loss [Abstract]
Sales	$ 269,581	$ 313,208	$ 925,362	$ 756,954
Cost of sales	105,403	90,435	306,072	218,898
Gross margin	164,178	222,773	619,290	538,056
Operating expenses:
Research and development	1,140,577	995,620	3,030,467	3,235,022
Sales and marketing	43,284	31,010	87,931	281,583
General and administrative	1,087,363	596,778	3,030,749	1,790,595
Depreciation and amortization	144,399	164,242	449,211	499,534
Total operating expenses	2,415,623	1,787,650	6,598,358	5,806,734
Loss from operations	(2,251,445)	(1,564,877)	(5,979,068)	(5,268,678)
Other income (expense):
Interest income, net	1,649	342	1,957	22,298
Other income	0	0	821,515	0
Interest expense	(7,055)	(3,760)	(14,546)	(9,093)
Other expenses	(2,850)	0	(2,850)	0
Total other income (expense)	(8,256)	(3,418)	806,076	13,205
Loss before income taxes	(2,259,701)	(1,568,295)	(5,172,992)	(5,255,473)
Income tax expense	0	0	0	0
Net loss	(2,259,701)	(1,568,295)	(5,172,992)	(5,255,473)
Comprehensive loss:
Net loss	(2,259,701)	(1,568,295)	(5,172,992)	(5,255,473)
Change in fair value of available for sale investments	0	0	0	(20)
Total comprehensive loss	(2,259,701)	(1,568,295)	(5,172,992)	(5,255,493)
Net loss attributable to common stockholders, basic (in dollars per share)	(2,259,701)	(1,568,295)	(5,172,992)	(5,255,473)
Net loss attributable to common stockholders, diluted (in dollars per share)	$ (2,259,701)	$ (1,568,295)	$ (5,172,992)	$ (5,255,473)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.19)	$ (1.64)	$ (1.04)	$ (5.50)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.19)	$ (1.64)	$ (1.04)	$ (5.50)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	11,799,720	955,649	4,996,680	955,402
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	11,799,720	955,649	4,996,680	955,402

Statement of Stockholders' Defi

Statement of Stockholders' Deficit - USD ($)	Common Stock [Member]	Treasury Stock [Member]	Preferred Stock [Member]	Warrants [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss, Net of Tax [Member]	Accumulated Deficit [Member]	Total	Series B and Series C Redeemable Convertible Preferred Stock [Member]
Balance at Dec. 31, 2019									$ 55,343,686
Balance (in shares) at Dec. 31, 2019									55,835,833
Increase (Decrease) in Temporary Equity [Roll Forward]
Share-based compensation expense									$ 0
Net loss									0
Other comprehensive income									0
Balance at Sep. 30, 2020									$ 55,343,686
Balance (in shares) at Sep. 30, 2020									55,835,833
Balance at Dec. 31, 2019	$ 1,057	$ (60,000)	$ 17,211	$ 702,492	$ 22,254,162	$ 20	$ (68,287,498)	$ (45,372,556)
Balance (in shares) at Dec. 31, 2019	1,057,291	117,223	17,210,609
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for cash upon exercise of options	$ 16	$ 0	$ 0	0	55,534	0	0	55,550
Issuance of common stock for cash upon exercise of options (in shares)	15,834	0	0
Share-based compensation expense	$ 0	$ 0	$ 0	0	239,075	0	0	239,075
Net loss	0	0	0	0	0	0	(5,255,473)	(5,255,473)
Other comprehensive income	0	0	0	0	0	(20)	0	(20)
Balance at Sep. 30, 2020	$ 1,073	$ (60,000)	$ 17,211	702,492	22,548,771	0	(73,542,971)	(50,333,424)
Balance (in shares) at Sep. 30, 2020	1,073,125	117,223	17,210,609
Balance at Jun. 30, 2020									$ 55,343,686
Balance (in shares) at Jun. 30, 2020									55,835,833
Increase (Decrease) in Temporary Equity [Roll Forward]
Share-based compensation expense									$ 0
Net loss									0
Other comprehensive income									0
Balance at Sep. 30, 2020									$ 55,343,686
Balance (in shares) at Sep. 30, 2020									55,835,833
Balance at Jun. 30, 2020	$ 1,072	$ (60,000)	$ 17,211	702,492	22,465,251	0	(71,974,676)	(48,848,650)
Balance (in shares) at Jun. 30, 2020	1,072,569	117,223	17,210,609
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for cash upon exercise of options	$ 1	$ 0	$ 0	0	2,749	0	0	2,750
Issuance of common stock for cash upon exercise of options (in shares)	556	0	0
Share-based compensation expense	$ 0	$ 0	$ 0	0	80,771	0	0	80,771
Net loss	0	0	0	0	0	0	(1,568,295)	(1,568,295)
Other comprehensive income	0	0	0	0	0	0	0	0
Balance at Sep. 30, 2020	$ 1,073	$ (60,000)	$ 17,211	702,492	22,548,771	0	(73,542,971)	(50,333,424)
Balance (in shares) at Sep. 30, 2020	1,073,125	117,223	17,210,609
Balance at Dec. 31, 2020									$ 55,343,686
Balance (in shares) at Dec. 31, 2020									55,835,833
Increase (Decrease) in Temporary Equity [Roll Forward]
Automatic conversion of preferred stock in connection with IPO									$ (55,343,686)
Automatic conversion of preferred stock in connection with IPO (in shares)									(55,835,833)
Share-based compensation expense									$ 0
Net loss									0
Other comprehensive income									0
Balance at Sep. 30, 2021									$ 0
Balance (in shares) at Sep. 30, 2021									0
Balance at Dec. 31, 2020	$ 1,110	$ (60,000)	$ 17,211	702,492	22,725,949	0	(75,202,490)	(51,815,728)
Balance (in shares) at Dec. 31, 2020	1,110,347	117,223	17,210,609
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for cash upon exercise of options	$ 40	$ 0	$ 0	0	112,105	0	0	$ 112,145
Issuance of common stock for cash upon exercise of options (in shares)	40,253	0	0					40,253
Issuance of common stock in connection with IPO, net	$ 2,650	$ 0	$ 0	0	30,019,707	0	0	$ 30,022,357
Issuance of common stock in connection with IPO, net (in shares)	2,650,000	0	0
Automatic conversion of preferred stock in connection with IPO	$ 8,116	$ 0	$ (17,211)	0	55,352,781	0	0	55,343,686
Automatic conversion of preferred stock (in shares)	8,116,343	0	(17,210,609)
Share-based compensation expense	$ 0	$ 0	$ 0	0	163,924	0	0	163,924
Net loss	0	0	0	0	0	0	(5,172,992)	(5,172,992)
Other comprehensive income	0	0	0	0	0	0	0	0
Balance at Sep. 30, 2021	$ 11,916	$ (60,000)	$ 0	702,492	108,374,466	0	(80,375,482)	28,653,392
Balance (in shares) at Sep. 30, 2021	11,916,943	117,223	0
Balance at Jun. 30, 2021									$ 0
Balance (in shares) at Jun. 30, 2021									0
Increase (Decrease) in Temporary Equity [Roll Forward]
Automatic conversion of preferred stock in connection with IPO									$ 0
Automatic conversion of preferred stock in connection with IPO (in shares)									0
Share-based compensation expense									$ 0
Net loss									0
Other comprehensive income									0
Balance at Sep. 30, 2021									$ 0
Balance (in shares) at Sep. 30, 2021									0
Balance at Jun. 30, 2021	$ 11,916	$ (60,000)	$ 0	702,492	108,341,078	0	(78,115,781)	30,879,705
Balance (in shares) at Jun. 30, 2021	11,916,943	117,223	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for cash upon exercise of options	$ 0	$ 0	$ 0	0	0	0	0	0
Issuance of common stock for cash upon exercise of options (in shares)	0	0	0
Issuance of common stock in connection with IPO, net	$ 0	$ 0	$ 0	0	0	0	0	0
Issuance of common stock in connection with IPO, net (in shares)	0	0	0
Automatic conversion of preferred stock in connection with IPO	$ 0	$ 0	$ 0	0	0	0	0	0
Automatic conversion of preferred stock (in shares)	0	0	0
Share-based compensation expense	$ 0	$ 0	$ 0	0	33,388	0	0	33,388
Net loss	0	0	0	0	0	0	(2,259,701)	(2,259,701)
Other comprehensive income	0	0	0	0	0	0	0	0
Balance at Sep. 30, 2021	$ 11,916	$ (60,000)	$ 0	$ 702,492	$ 108,374,466	$ 0	$ (80,375,482)	$ 28,653,392
Balance (in shares) at Sep. 30, 2021	11,916,943	117,223	0

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (5,172,992)	$ (5,255,473)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	417,188	419,435
Amortization	32,023	80,099
Amortization of discount on investments	0	(1,189)
Amortization of right-of-use assets	284,519	320,184
Share-based compensation expense	163,924	239,075
Loan and accrued interest forgiveness on note payable	(821,515)	0
Loss on disposal of fixed asset	2,850	0
Changes in operating assets and liabilities:
Accounts receivable	(17,669)	(37,105)
Inventory	(18,958)	15,549
Other assets	498,878	205,839
Accounts payable	(237,443)	4,426
Accrued expenses and other	(510,730)	634,621
Lease liabilites	(312,893)	(337,074)
Other liabilities	9,935	49,606
Net cash used in operating activities	(5,682,883)	(3,662,007)
Cash flows from investing activities:
Maturities of short-term investments	0	1,000,000
Purchases of property and equipment	(188,245)	(8,352)
Payments for patents and other intangible assets	0	(42,995)
Net cash (used in) provided by investing activities	(188,245)	948,653
Cash flows from financing activities:
Proceeds from issuance of common stock	31,725,645	55,550
Payments of offering costs	(1,578,643)	0
Proceeds from note payable and advance	0	822,500
Repayment of note payable	(302,343)	0
Payments under lease obligations	(15,448)	(13,977)
Net cash provided by financing activities	29,829,211	864,073
Net change in cash and cash equivalents	23,958,083	(1,849,281)
Cash and cash equivalents:
Beginning of the period	3,322,226	6,415,274
End of the period	27,280,309	4,565,993
Cash paid for:
Interest	11,155	5,487
Income taxes	800	2,000
Non-cash investing and financing activities:
Prepaid insurance financed with promissory notes	320,866	0
Conversion of convertible preferred stock to common stock	$ 55,360,897	$ 0

Organization, Nature of Busines

Organization, Nature of Business, and Liquidity	9 Months Ended
	Sep. 30, 2021
Organization, Nature of Business, and Liquidity [Abstract]
Organization, Nature of Business, and Liquidity	(1) Organization, Nature of Business, and Liquidity Organization and Nature of Business Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. Our mission is to provide women worldwide with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The Company currently operates as one segment and is focused on servicing the reproductive health needs for those seeking permanent birth control or solutions for infertility issues. Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing. FemBloc® (FemBloc), the Company’s solution for permanent birth control, is based on the Company’s non-surgical platform technology and is presently completing a validation study under an approved Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA). FemaSeed® (FemaSeed), a solution which enables directed intrauterine insemination to improve on traditional intrauterine insemination (IUI) and provide a lower cost option to in vitro fertilization methods, received approval in April 2021 from the FDA on its IDE and the clinical study was initiated in July 2021. FemVue® Saline-Air Device (FemVue) is a product approved for sale in the U.S., Europe, Japan, and Canada for the diagnosis of infertility. FemChec® Pressure Management Device (FemChec) evaluates the women’s fallopian tubes after a FemBloc procedure and is part of the FemBloc validation study. FemCerv® Endocervical Sampler (FemCerv) is designed to collect a complete, non-contaminated cervical tissue sample. Initial Public Offering On June 22, 2021, the Company closed its initial public offering (the IPO) in which it issued and sold 2,650,000 shares of its authorized common stock. The price per share in the IPO was $13.00 . Net proceeds received by the Company, after deducting underwriting discounts, commissions, and legal expenses, were $31,613,500. Offering costs incurred by the Company were $1,591,144, which excludes legal expenses incurred by our underwriters of $425,000. Immediately prior to the closing of the IPO, all our shares of our convertible Series A preferred stock and our redeemable convertible Series B and Series C preferred stock automatically converted into 8,116,343 shares of common stock. Basis of Presentation The Company has prepared the accompanying financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2020 included in our final prospectus (Prospectus) dated June 17, 2021 and filed with the SEC, pursuant to Rule 424(b) under the Securities Act of 1933, as amended, or the Securities Act, on June 21, 2021 (Registration No. 333-256156). Except as noted below, there have been no material changes to the Company’s significant accounting policies described in Note 2 to the financial statements included in the Prospectus. In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock options, warrants, useful lives of property and equipment, intangible assets, and the pre-IPO valuation of our common stock and preferred stock. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates. Liquidity As of September 30, 2021, the Company has cash and cash equivalents of $27,280,309. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, in the future with additional equity and/or debt financing arrangements, and revenue from the sale of FemVue to support the Company’s research and development activities, largely in connection with FemBloc and FemaSeed. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the nine months ended September 30, 2021, the Company generated a net loss of $5,172,992. The Company expects such losses to increase over the next few years as the Company advances FemBloc and FemaSeed through clinical development until FDA approval is received and the products are available to be marketed. The Company believes that its cash and cash equivalents as of September 30, 2021 will be sufficient to fund its operating expenses and research & development expenditure requirements through at least one year after the issuance date of the financial statements for the nine months ended September 30, 2021. The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Recently Issued Accounting Pronouncements – Recently Adopted On January 1, 2021, the Company adopted Accounting Standards Update (ASU) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recently Issued Accounting Pronouncements – Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses Measurement of Credit Losses on Financial Instruments No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2021
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	(2) Cash and Cash Equivalents As of September 30, 2021 and December 31, 2020, money market funds included in cash and cash equivalents on the balance sheets were $0 and $3,038,612, respectively, which represent level 1 within the fair value hierarchy where there are quoted prices in active markets for identical assets.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2021
Inventories [Abstract]
Inventories	(3) Inventories Inventory stated at cost, net of reserve, consisted of the following: September 30, 2021 December 31, 2020 Materials $ 85,655 61,270 Work in progress 39,879 49,650 Finished goods 24,802 20,458 Inventory, net $ 150,336 131,378 The reserve for expired inventories pertaining to FemVue was $358 and $896 as of September 30, 2021 and December 31, 2020, respectively.

Deferred Offering Costs

Deferred Offering Costs	9 Months Ended
	Sep. 30, 2021
Deferred Offering Costs [Abstract]
Deferred Offering Costs	(4) Deferred Offering Costs Deferred offering costs, which consisted mainly of legal, consulting, and accounting fees directly attributable to a strategic financing transaction, were capitalized in accordance with Staff Accounting Bulletin (SAB) Topic 5.A, codified in Accounting Standards Codification (ASC) 340-10-S99-1. In May 2021, the Company expensed $188,544 of deferred offering costs in connection with another financing transaction to focus on the IPO transaction. In June 2021, upon the closing of the IPO, total deferred offering costs of $1,591,144 were offset against the proceeds of the IPO offering. As of September 30, 2021, no amounts of deferred offering costs were capitalized. As of December 31, 2020, deferred offering costs capitalized were $202,479 and are included in other long-term assets in the accompanying balance sheets.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Accrued Expenses [Abstract]
Accrued Expenses	(5) Accrued Expenses Accrued expenses consisted of the following: September 30, 2021 December 31, 2020 Clinical trial costs $ 261,885 289,180 Compensation costs 146,034 796,864 Other 189,937 31,557 Accrued expenses $ 597,856 1,117,601

Clinical Holdback

Clinical Holdback	9 Months Ended
	Sep. 30, 2021
Clinical Holdback [Abstract]
Clinical Holdback	(6) Clinical Holdback The following table shows the activity within the clinical holdback liability accounts for the nine months ended September 30, 2021: Balance at December 31, 2020 $ 164,972 Clinical holdback retained 15,016 Clinical holdback paid (5,081 ) Balance at September 30 2021 $ 174,907 Less: clinical holdback - current portion (18,947 ) Clinical holdback - long-term portion $ 155,960

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2021
Revenue Recognition [Abstract]
Revenue Recognition	(7) Revenue Recognition Revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time. For the three and nine months ended September 30, 2021 and 2020, there was no revenue recognized from performance obligations satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of September 30, 2021 and December 31, 2020. The majority of products sold directly to U.S customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. Throughout the periods presented, the Company has not had a history of significant returns. The following table summarizes our FemVue sales by geographic region as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Primary geographical markets U.S. $ 211,536 255,163 751,285 638,672 International 58,045 58,045 174,077 118,282 Total $ 269,581 313,208 925,362 756,954

Other Income

Other Income	9 Months Ended
	Sep. 30, 2021
Other Income [Abstract]
Other Income	(8) Other Income In June 2021, the Company was notified by Georgia Primary Bank that the Paycheck Protection Program (PPP) loan in the amount of $812,500 and accrued interest of $9,015 was fully forgiven. For the nine months ended September 30, 2021, the Company recorded $821,515 in other income in connection with the Small Business Administration (SBA) PPP loan forgiveness program, and no other income was recorded for the three months ended September 30, 2021. For the three and nine months ended September 30, 2020, there was no other income recorded.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies [Abstract]
Commitments and Contingencies	(9) Commitments and Contingencies Legal Claims Occasionally, the Company may be a party to legal claims or proceedings of which the outcomes are subject to significant uncertainty. In accordance with ASC 450, Contingencies The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The Company entered into employment agreements with its officers, which provides for indemnification protection in the executive’s capacity as an officer for actions taken within the scope of employment. The maximum amount of potential future indemnification is unlimited; however, the Company has obtained director and officer insurance that limits its exposure. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of September 30, 2021 and December 31, 2020.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2021
Notes Payable [Abstract]
Notes Payable	(10) Notes Payable Paycheck Protection Program Loan In April 2020, the Company executed a promissory note (Note) with Georgia Primary Bank (the Lender) evidencing an unsecured loan in the amount of $812,500, which was made pursuant to the PPP. The PPP was established under the Coronavirus Aid, Relief and Economic Security Act (CARES Act), which was enacted on March 27, 2020, and is administered by the SBA. All the funds under the PPP loan were disbursed to the Company in April 2020 and was recognized as debt on the Company’s financial statements. The Note provided for a fixed interest rate of one percent per year, and the Company was not imputing any additional interest at a market rate because this was a government-guaranteed obligation. Monthly principal and interest payments of $45,717 on the PPP loan were due beginning November 2020 April 2022 Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of the loans granted under the PPP. Such forgiveness is subject to approval by the SBA and the Lender and determined, subject to limitations, based on factors set forth in the CARES Act, including verification of the use of loan proceeds for payment of payroll costs and payment of mortgage interest, rent, and utilities. In the event the PPP loan, or any portion thereof, is forgiven, it is applied to outstanding principal. As of September 30, 2020, the Company had used all the proceeds from the PPP loan to retain employees, maintain payroll, and make lease and utility payments. In October 2020, the Company submitted the loan forgiveness application to the Lender requesting forgiveness for the full amount of the loan. The Lender had 60 days from receipt of the loan forgiveness application to issue a decision to the SBA, and the SBA, subject to its review, would remit funds within 90 days after the Lender issues its decision to the SBA. In June 2021, the Company was notified by the Lender that the PPP Loan in the amount of $812,500 and accrued interest of $9,015 was fully forgiven; and, as a result, the entire amount was derecognized on the Company’s financial statements, which was included as other income for the nine months ended September 30, 2021 on the accompanying statements of comprehensive loss. The SBA reserves the right to audit our fully forgiven PPP loan for an indefinite time. As of September 30, 2021, no amounts were outstanding under the PPP loan. As of December 31, 2020, the PPP loan balance consisted of $630,010 payable in 2021 and $182,490 in 2022, and interest expense accrued in connection with this PPP loan was $5,654 and was included in accrued expenses on the accompanying balance sheets. For the three months ended September 30, 2021 and 2020, interest expense on the PPP loan was $0 and $2,048, respectively. For the nine months ended September 30, 2021 and 2020, interest expense on the PPP loan was $3,361 and $3,606, respectively. Economic Injury Disaster Loan advance In April 2020, the Company received the SBA Economic Injury Disaster Loan advance (EIDL advance) of $10,000. This EIDL advance was originally included in notes payable since the SBA was required to deduct the amount of any EIDL advance received by a PPP borrower from the PPP forgiveness payment remitted by SBA to the lender. In December 2020, the Economic Aid to Hard-Hit Small Business, Nonprofits and Venues Act (Economic Aid Act) was signed into law, which repealed the SBA requirement to deduct the amount of any EIDL advance received by a PPP borrower from the PPP forgiveness payment. As a result of the Economic Aid Act, the Company recognized the EIDL advance as other income in December 2020. As of September 30, 2021 and December 31, 2020 no amounts were outstanding under the EIDL advance. For the three and nine months ending September 30, 2021 and 2020, no amounts were recognized as EIDL other income. AFCO Credit Corporation (AFCO) In the first quarter of 2021, the Company executed two Promissory Notes with AFCO (AFCO notes) to finance certain insurance premiums totaling $64,842, requiring the Company to pay $16,210 in down payments and make monthly installment payments. The annual interest rate is 10.5% and the current monthly installment payments total $6,094, which represents principal and interest. The final installment payments were paid on October 12, 2021. In the second quarter of 2021, the Company executed another Promissory Note with AFCO (AFCO note) to finance certain insurance premiums totaling $558,367, requiring the Company to pay $111,673 in a down payment and make monthly installment payments. The annual interest rate is 5.25% and the monthly installment payment is $45,751, which represents principal and interest. The final installment payment is due April 18, 2022. As of September 30, 2021, the principal balance on all the AFCO promissory notes was $320,866 and is included in Notes payable – current portion in the accompanying balance sheets. Interest expense in connection with the three AFCO promissory notes was $5,846 and $0 for the three months ended September 30, 2021 and 2020, respectively; and interest expense in connection with the three AFCO promissory notes was $7,170 and $0 for the nine months ended September 30, 2021 and 2020, respectively.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock and Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Redeemable Convertible Preferred Stock and Stockholders' Equity [Abstract]
Redeemable Convertible Preferred Stock and Stockholders' Equity	(11) Redeemable Convertible Preferred Stock and Stockholders’ Equity On June 22, 2021, the Company issued 2,650,000 shares of common stock in connection with the Company’s IPO of its common stock at $13.00 per share. Net proceeds to the Company, after deducting underwriting discounts, commissions, and legal expenses, was $31,613,500. Offering costs incurred by the company were $1,591,144. Immediately prior to the closing of the IPO, all our shares of our convertible Series A preferred stock and our redeemable convertible Series B and Series C preferred stock automatically converted into 8,116,343 shares of common stock. The Company filed an eleventh amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the completion of the IPO on June 22, 2021. The Amended and Restated Certificate amends and restates the Company’s existing certificate of incorporation in its entirety to, among other things: (i) authorize 200,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock (Series A, B and C); and (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series. (a) Common Stock The holders of the common stock shall have the exclusive right to vote for the election of directors and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote; provided, however, that, except as otherwise required by law, holders of common stock, as such, shall not be entitled to vote on any amendment to the Amended and Restated Certificate (or on any amendment to a certificate of designations of any series of preferred stock) that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of preferred stock if the holders of such affected series of preferred stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to this Amended and Restated Certificate (or pursuant to a certificate of designations of any series of preferred stock). Dividends may be declared and paid or set apart for payment upon the common stock out of any assets or funds of the Company legally available for the payment of dividends, but only when and as declared by the Board of Directors or any authorized committee thereof. Upon the voluntary or involuntary liquidation, dissolution or winding up of the Company, the net assets of the Company shall be distributed pro rata to the holders of the common stock. (b) Preferred Stock The Board of Directors is authorized to direct the Company to issue shares of preferred stock in one or more series without stockholder approval. Our Board of Directors has the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. As of September 30, 2021, the Company had 11,799,720 shares of common stock outstanding, and no dividends have been declared or paid.

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Sep. 30, 2021
Equity Incentive Plans [Abstract]
Equity Incentive Plans	(12) Equity Incentive Plans Stock Option Plans In June 2021, in connection with the IPO, our 2021 Equity Incentive Plan (“2021 Plan”) became effective, which was adopted by our Board of Directors in February 2021 and our stockholders approved the 2021 Plan in March 2021. The 2021 Plan is administered by our compensation committee. Upon the effectiveness of the 2021 Plan, no new grants will be awarded under our 2015 Stock-Based Incentive Compensation Plan. Under the 2021 Plan, the Company may grant awards in respect of our shares of common stock to our employees, consultants, and our non-employee directors pursuant to option awards, stock appreciation right, or SAR, awards, restricted stock awards, restricted stock unit, or RSU, awards, performance stock awards, performance stock unit, or PSU, awards, and other stock-based awards. The total number of shares of common stock available for awards under the 2021 Plan is 1,111,111, provided that such number shall be automatically increased on each January 1, beginning on January 1, 2022, by 4% of the outstanding number of shares of our common stock on the immediately preceding December 31 or such lesser number of shares as determined by our Board of Directors. The aggregate number of shares of our common stock that will be available for issuance under awards granted pursuant to the 2021 Plan shall also be increased by the number of shares underlying the portion of an award granted under our 2015 Plan that is cancelled, terminated or forfeited or lapses after the effective date of the 2021 Plan. No more than 1,111,111 shares of common stock issued under the 2021 Plan may be issued pursuant to the exercise of incentive stock options (ISO), provided that such number shall be automatically increased on each January 1, beginning on January 1, 2022, by the lesser of 4% of the outstanding number of shares of our common stock on the immediately preceding December 31 or 555,555 shares of common stock. Shares of common stock issued by us in connection with the assumption or substitution of outstanding grants or under certain stockholder approved plans from an acquired company shall not reduce the number of shares of common stock available for awards under the 2021 Plan. Shares of common stock underlying the portion of an award that is forfeited or otherwise terminated for any reason whatsoever, in any case, without the issuance of shares of common stock, will be added back to the number of shares of common stock available for grant under the 2021 Plan. No non-employee director may be granted awards under the 2021 Plan in any one calendar year covering a number of shares of common stock that have a fair market value on the grant date in excess of $350,000 in the first calendar year of such non-employee director’s initial service as a non-employee director and $200,000 in any other calendar year of such non-employee director’s service as a non-employee director. Options granted under the 2021 Plan may be either ISOs, or nonqualified stock options. The price at which shares of common stock may be purchased upon exercise shall be determined by the compensation committee but shall not be less than the fair market value of one share of common stock on the date of grant, or, in the case of an ISO granted to a ten-percent Activity under the stock option plans was as follows: Number of Options Weighted Average Exercise Price Balances at December 31, 2020 743,627 $ 3.60 Granted — — Exercised (40,253 ) 2.79 Cancelled (7,211 ) 7.07 Balances at September 30, 2021 696,163 $ 3.58 The intrinsic value of options exercised during the nine months ended September 30, 2021 was $145,053. The intrinsic values represent the dollar value of the exercised stock options whereby the fair market value of the underlying common stock exceeded the exercise price of the stock option as of the exercise date. The options outstanding and vested and currently exercisable by exercise prices as of September 30, 2021 were as follows: Option outstanding Options vested and exercisable Exercise price Outstanding (in shares) Weighted average remaining life years Number of options vested Exercise price Weighted average remaining life years $ 1.71 227,780 4.46 116,669 $ 1.71 4.46 3.24 284,282 5.75 284,282 3.24 5.75 3.96 67,422 6.46 54,645 3.96 6.45 4.50 1,667 7.12 834 4.50 7.12 4.95 44,445 7.49 22,223 4.95 7.49 6.12 58,342 8.20 17,091 6.12 8.20 27.00 12,225 0.82 12,225 27.00 0.82 696,163 5.63 507,969 5.57 For the three months ended September 30, 2021 and 2020, stock-based compensation expense was $33,388 and $80,771, respectively. For the nine months ended September 30, 2021 and 2020, stock-based compensation expense was $163,924 and $239,075, respectively. As of September 30, 2021, the remaining stock-based compensation expense that is expected to be recognized in future periods for employees and nonemployees is $320,193, which includes $155,222 of compensation expense to be recognized upon achieving a certain performance condition. For service based awards, the $164,971 of unrecognized expense is expected to be recognized over a weighted average period of 1.7 years. Employee Stock Purchase Plan (“ESPP”) In June 2021, in connection with the IPO, our ESPP became effective which was adopted by our Board of Directors in February 2021 and our stockholders approved the 2021 ESPP Plan in March 2021. The ESPP is administered by our compensation committee. The total number of shares of our common stock available for purchase under the ESPP is 166,666, provided that such number is automatically increased on January 1 of each calendar year, from January 1, 2022 through January 1, 2031 by the least of (i) 1.0% of the total number of shares of our common stock outstanding on December 31 of the immediately preceding calendar year, (ii) 222,222 shares of our common stock or (iii) a number determined by our board of directors that is less than the foregoing clauses (i) and (ii). Under the ESPP, the Company may specify offerings with durations of not more than 27 months and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances. No employee may purchase more than 12,254 shares of our common stock under the ESPP during any offering period. Unless otherwise determined by our board of directors, shares of common stock will be purchased for accounts of employees participating in the ESPP at a price per share equal to the lower of (i) 85% of the fair market value of a share of our common stock on the last date of an offering period or (ii) 85% of the fair market value of a share of our common stock on the first day of such offering period. As September 30, 2021, no shares of our common stock have been purchased under the ESPP.

Net Loss per Share Attributable

Net Loss per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2021
Net Loss per Share Attributable to Common Stockholders [Abstract]
Net Loss per Share Attributable to Common Stockholders	(13) Net Loss per Share Attributable to Common Stockholders The following ta ble sets forth the computation of t Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net loss attributable to common stockholders, basic & diluted $ (2,259,701 ) (1,568,295 ) (5,172,992 ) (5,255,473 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic & diluted 11,799,720 955,649 4,996,680 955,402 Net loss per share attributable to common stockholders, basic & diluted $ (0.19 ) (1.64 ) (1.04 ) (5.50 ) The following potentially dilutive secur Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Convertible preferred stock outstanding — 8,116,343 — 8,116,343 Options to purchase common stock 696,163 780,862 696,163 780,862 Warrants to purchase common stock 244,572 244,572 244,572 244,572 Total potential shares 940,735 9,141,777 940,735 9,141,777

Organization, Nature of Busin_2

Organization, Nature of Business, and Liquidity (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Nature of Business, and Liquidity [Abstract]
Organization and Nature of Business	Organization and Nature of Business Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. Our mission is to provide women worldwide with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The Company currently operates as one segment and is focused on servicing the reproductive health needs for those seeking permanent birth control or solutions for infertility issues. Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing. FemBloc® (FemBloc), the Company’s solution for permanent birth control, is based on the Company’s non-surgical platform technology and is presently completing a validation study under an approved Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA). FemaSeed® (FemaSeed), a solution which enables directed intrauterine insemination to improve on traditional intrauterine insemination (IUI) and provide a lower cost option to in vitro fertilization methods, received approval in April 2021 from the FDA on its IDE and the clinical study was initiated in July 2021. FemVue® Saline-Air Device (FemVue) is a product approved for sale in the U.S., Europe, Japan, and Canada for the diagnosis of infertility. FemChec® Pressure Management Device (FemChec) evaluates the women’s fallopian tubes after a FemBloc procedure and is part of the FemBloc validation study. FemCerv® Endocervical Sampler (FemCerv) is designed to collect a complete, non-contaminated cervical tissue sample.
Initial Public Offering	Initial Public Offering On June 22, 2021, the Company closed its initial public offering (the IPO) in which it issued and sold 2,650,000 shares of its authorized common stock. The price per share in the IPO was $13.00 . Net proceeds received by the Company, after deducting underwriting discounts, commissions, and legal expenses, were $31,613,500. Offering costs incurred by the Company were $1,591,144, which excludes legal expenses incurred by our underwriters of $425,000. Immediately prior to the closing of the IPO, all our shares of our convertible Series A preferred stock and our redeemable convertible Series B and Series C preferred stock automatically converted into 8,116,343 shares of common stock.
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2020 included in our final prospectus (Prospectus) dated June 17, 2021 and filed with the SEC, pursuant to Rule 424(b) under the Securities Act of 1933, as amended, or the Securities Act, on June 21, 2021 (Registration No. 333-256156). Except as noted below, there have been no material changes to the Company’s significant accounting policies described in Note 2 to the financial statements included in the Prospectus. In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock options, warrants, useful lives of property and equipment, intangible assets, and the pre-IPO valuation of our common stock and preferred stock. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.
Liquidity	Liquidity As of September 30, 2021, the Company has cash and cash equivalents of $27,280,309. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, in the future with additional equity and/or debt financing arrangements, and revenue from the sale of FemVue to support the Company’s research and development activities, largely in connection with FemBloc and FemaSeed. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the nine months ended September 30, 2021, the Company generated a net loss of $5,172,992. The Company expects such losses to increase over the next few years as the Company advances FemBloc and FemaSeed through clinical development until FDA approval is received and the products are available to be marketed. The Company believes that its cash and cash equivalents as of September 30, 2021 will be sufficient to fund its operating expenses and research & development expenditure requirements through at least one year after the issuance date of the financial statements for the nine months ended September 30, 2021. The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.
Recently Issued Accounting Pronouncements Adopted and Not Yet Adopted	Recently Issued Accounting Pronouncements – Recently Adopted On January 1, 2021, the Company adopted Accounting Standards Update (ASU) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recently Issued Accounting Pronouncements – Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses Measurement of Credit Losses on Financial Instruments No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Inventories [Abstract]
Inventory Stated at Cost, Net of Reserve	Inventory stated at cost, net of reserve, consisted of the following: September 30, 2021 December 31, 2020 Materials $ 85,655 61,270 Work in progress 39,879 49,650 Finished goods 24,802 20,458 Inventory, net $ 150,336 131,378

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Accrued Expenses [Abstract]
Accrued Expenses	Accrued expenses consisted of the following: September 30, 2021 December 31, 2020 Clinical trial costs $ 261,885 289,180 Compensation costs 146,034 796,864 Other 189,937 31,557 Accrued expenses $ 597,856 1,117,601

Clinical Holdback (Tables)

Clinical Holdback (Tables)	9 Months Ended
	Sep. 30, 2021
Clinical Holdback [Abstract]
Clinical Holdback Liability	The following table shows the activity within the clinical holdback liability accounts for the nine months ended September 30, 2021: Balance at December 31, 2020 $ 164,972 Clinical holdback retained 15,016 Clinical holdback paid (5,081 ) Balance at September 30 2021 $ 174,907 Less: clinical holdback - current portion (18,947 ) Clinical holdback - long-term portion $ 155,960

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue Recognition [Abstract]
Sales by Geographic Region	The following table summarizes our FemVue sales by geographic region as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Primary geographical markets U.S. $ 211,536 255,163 751,285 638,672 International 58,045 58,045 174,077 118,282 Total $ 269,581 313,208 925,362 756,954

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2021
Equity Incentive Plans [Abstract]
Stock Option Plan Activity	Activity under the stock option plans was as follows: Number of Options Weighted Average Exercise Price Balances at December 31, 2020 743,627 $ 3.60 Granted — — Exercised (40,253 ) 2.79 Cancelled (7,211 ) 7.07 Balances at September 30, 2021 696,163 $ 3.58
Options Outstanding and Vested and Currently Exercisable by Exercise Prices	The options outstanding and vested and currently exercisable by exercise prices as of September 30, 2021 were as follows: Option outstanding Options vested and exercisable Exercise price Outstanding (in shares) Weighted average remaining life years Number of options vested Exercise price Weighted average remaining life years $ 1.71 227,780 4.46 116,669 $ 1.71 4.46 3.24 284,282 5.75 284,282 3.24 5.75 3.96 67,422 6.46 54,645 3.96 6.45 4.50 1,667 7.12 834 4.50 7.12 4.95 44,445 7.49 22,223 4.95 7.49 6.12 58,342 8.20 17,091 6.12 8.20 27.00 12,225 0.82 12,225 27.00 0.82 696,163 5.63 507,969 5.57

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2021
Net Loss per Share Attributable to Common Stockholders [Abstract]
Computation of Basic and Diluted Net Loss Per Share	The following ta ble sets forth the computation of t Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net loss attributable to common stockholders, basic & diluted $ (2,259,701 ) (1,568,295 ) (5,172,992 ) (5,255,473 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic & diluted 11,799,720 955,649 4,996,680 955,402 Net loss per share attributable to common stockholders, basic & diluted $ (0.19 ) (1.64 ) (1.04 ) (5.50 )
Computations of Diluted Weighted Average Shares Outstanding	The following potentially dilutive secur Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Convertible preferred stock outstanding — 8,116,343 — 8,116,343 Options to purchase common stock 696,163 780,862 696,163 780,862 Warrants to purchase common stock 244,572 244,572 244,572 244,572 Total potential shares 940,735 9,141,777 940,735 9,141,777

Organization, Nature of Busin_3

Organization, Nature of Business, and Liquidity (Details)	Jun. 22, 2021USD ($)$ / sharesshares	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)Segment	Sep. 30, 2020USD ($)	May 31, 2021USD ($)	Dec. 31, 2020USD ($)
Organization and Nature of Business [Abstract]
Number of operating segments | Segment				1
Initial Public Offering [Abstract]
Offering cost	$ 1,591,144					$ 188,544
Liquidity [Abstract]
Cash and cash equivalents		$ 27,280,309		$ 27,280,309			$ 3,322,226
Net loss		$ (2,259,701)	$ (1,568,295)	$ (5,172,992)	$ (5,255,473)
Initial Public Offering [Member]
Initial Public Offering [Abstract]
Shares issued and sold (in shares) | shares	2,650,000
Share price (in dollars per share) | $ / shares	$ 13
Proceeds from issuance after deducting underwriting discounts, commissions, and legal expenses	$ 31,613,500
Offering cost	1,591,144
Offering cost excludes legal expenses incurred underwriters	$ 425,000
Automatic conversion of preferred stock (in shares) | shares	8,116,343

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Level 1 [Member] | Money Market Funds [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalent	$ 0	$ 3,038,612

Inventories (Details)

Inventories (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Inventories [Abstract]
Materials	$ 85,655	$ 61,270
Work in progress	39,879	49,650
Finished goods	24,802	20,458
Inventory, net	150,336	131,378
Reserve for expired inventory	$ 358	$ 896

Deferred Offering Costs (Detail

Deferred Offering Costs (Details) - USD ($)	Sep. 30, 2021	Jun. 22, 2021	May 31, 2021	Dec. 31, 2020
Deferred Offering Costs [Abstract]
Deferred offering costs		$ 1,591,144	$ 188,544
Deferred offering costs capitalized	$ 0			$ 202,479

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accrued Expenses [Abstract]
Clinical trail costs	$ 261,885	$ 289,180
Compensation costs	146,034	796,864
Other	189,937	31,557
Accrued expenses	$ 597,856	$ 1,117,601

Clinical Holdback (Details)

Clinical Holdback (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Clinical Holdback Liability [Roll Forward]
Balance	$ 164,972
Clinical holdback retained	15,016
Clinical holdback paid	(5,081)
Balance	174,907
Less: clinical holdback - current portion	(18,947)	$ 0
Clinical holdback - long-term portion	$ 155,960	$ 164,972

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue Recognition [Abstract]
Revenue recognized from performance obligations in prior periods	$ 0	$ 0	$ 0	$ 0
Percentage of restocking fee			30.00%
Primary Geographical Markets [Abstract]
Sales	269,581	313,208	$ 925,362	756,954
FemVue [Member]
Primary Geographical Markets [Abstract]
Sales	269,581	313,208	925,362	756,954
FemVue [Member] | U.S. [Member]
Primary Geographical Markets [Abstract]
Sales	211,536	255,163	751,285	638,672
FemVue [Member] | International [Member]
Primary Geographical Markets [Abstract]
Sales	$ 58,045	$ 58,045	$ 174,077	$ 118,282
Minimum [Member]
Revenue Recognition [Abstract]
Revenue recognition payment period term			30 days
Maximum [Member]
Revenue Recognition [Abstract]
Revenue recognition payment period term			60 days

Other Income (Details)

Other Income (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Other Income [Abstract]
Other income		$ 0	$ 0	$ 821,515	$ 0
PPP Loan [Member] | Georgia Primary Bank [Member]
Other Income [Abstract]
Loan amount, forgiven	$ 812,500
Accrued interest, forgiven	$ 9,015

Notes Payable, Paycheck Protect

Notes Payable, Paycheck Protection Program Loan (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Apr. 30, 2020
Notes Payable [Abstract]
Notes payable in 2021		$ 320,866		$ 320,866		$ 630,010
Notes payable in 2022		0		0		182,490
PPP Loan [Member] | Georgia Primary Bank [Member]
Notes Payable [Abstract]
Loan amount		$ 0		$ 0			$ 812,500
Fixed interest rate		1.00%		1.00%
Frequency of installment payments				Monthly
Monthly principal and interest payments				$ 45,717
Maturity date of Loan, beginning				Nov. 30, 2020
Maturity date of Loan, ending				Apr. 30, 2022
Loan amount, forgiven	$ 812,500
Accrued interest, forgiven	$ 9,015
Notes payable in 2021		$ 0		$ 0		630,010
Notes payable in 2022						182,490
Accrued interest expense						$ 5,654
Interest expense		$ 0	$ 2,048	$ 3,361	$ 3,606

Notes Payable, Economic Injury

Notes Payable, Economic Injury Disaster Loan Advance (Details) - EIDL Advance [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Apr. 30, 2020
Notes Payable [Abstract]
Loan amount	$ 0		$ 0		$ 0	$ 10,000
Grant income	$ 0	$ 0	$ 0	$ 0

Notes Payable, AFCO Credit Corp

Notes Payable, AFCO Credit Corporation (Details)	3 Months Ended				9 Months Ended
	Sep. 30, 2021USD ($)PromissoryNote	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)PromissoryNote	Sep. 30, 2020USD ($)PromissoryNote	Sep. 30, 2021USD ($)PromissoryNote	Sep. 30, 2020USD ($)PromissoryNote	Dec. 31, 2020USD ($)
Notes Payable [Abstract]
Proceeds to pay insurance premiums					$ 0	$ 822,500
Down payments					302,343	$ 0
Notes payable - current portion	$ 320,866				320,866		$ 630,010
Promissory Notes [Member] | AFCO Credit Corporation [Member]
Notes Payable [Abstract]
Number of promissory notes executed | PromissoryNote			2
Proceeds to pay insurance premiums		$ 558,367	$ 64,842
Down payments		$ 111,673	$ 16,210
Interest rate		5.25%	10.50%
Frequency of installment payments		monthly	monthly
Monthly principal and interest payments		$ 45,751	$ 6,094
Maturity date of loan		Apr. 18, 2022	Oct. 12, 2021
Notes payable - current portion	$ 320,866				$ 320,866
Number of promissory notes | PromissoryNote	3			3	3	3
Interest expense on loan	$ 5,846			$ 0	$ 7,170	$ 0

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock and Stockholders' Equity (Details) - USD ($)	Jun. 22, 2021	Sep. 30, 2021	Sep. 30, 2021	May 31, 2021	Dec. 31, 2020
Stockholders Equity [Abstract]
Deferred offering costs	$ 1,591,144			$ 188,544
Number of votes per share			one
Common stock, outstanding (in shares)		11,799,720	11,799,720		993,124
Dividends declared or paid			$ 0
IPO [Member]
Stockholders Equity [Abstract]
Shares issued and sold (in shares)	2,650,000
Share price (in dollars per share)	$ 13
Proceeds from issuance after deducting underwriting discounts, commissions, and legal expenses	$ 31,613,500
Deferred offering costs	$ 1,591,144
Automatic conversion of preferred stock (in shares)	8,116,343
Common Stock [Member]
Stockholders Equity [Abstract]
Shares issued and sold (in shares)		0	2,650,000
Automatic conversion of preferred stock (in shares)		0	8,116,343
Number of shares authorized, for all classes of stock (in shares)		200,000,000	200,000,000
Preferred Stock [Member]
Stockholders Equity [Abstract]
Shares issued and sold (in shares)		0	0
Automatic conversion of preferred stock (in shares)		0	(17,210,609)
Number of shares authorized, for all classes of stock (in shares)		10,000,000	10,000,000

Equity Incentive Plans, Stock O

Equity Incentive Plans, Stock Option Plans (Details) - USD ($)	1 Months Ended	9 Months Ended
	Jun. 30, 2021	Sep. 30, 2021
Stock Option Plan [Abstract]
New grants awarded (in shares)		0
2015 Plan [Member]
Stock Option Plan [Abstract]
New grants awarded (in shares)	0
2021 Plan [Member]
Stock Option Plan [Abstract]
Number of shares of common stock available for awards (in shares)		1,111,111
Percentage of increase in outstanding number of shares of common stock		4.00%
Number of shares approved to increase (in shares)		555,555
Common stock fair market value on grant date for first calendar year		$ 350,000
Common stock fair market value on grant date for other calendar year		$ 200,000
Percentage of Incentive Stock Options granted to stockholders		10.00%
Contract term of stock option		10 years
Contract term if ISO granted to ten-percent shareholders		5 years
2021 Plan [Member] | Maximum [Member]
Stock Option Plan [Abstract]
Percentage of ISO granted to ten-percent shareholder		110.00%

Equity Incentive Plans, Stock_2

Equity Incentive Plans, Stock Option Plan, Activity (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Number of Options [Roll Forward]
Beginning balance (in shares) | shares	743,627
Granted (in shares) | shares	0
Exercised (in shares) | shares	(40,253)
Cancelled (in shares) | shares	(7,211)
Ending balance (in shares) | shares	696,163
Weighted Average Exercise Price [Abstract]
Beginning balance (in dollars per share) | $ / shares	$ 3.60
Granted (in dollars per share) | $ / shares	0
Exercised (in dollars per share) | $ / shares	2.79
Forfeited (in dollars per share) | $ / shares	7.07
Ending balance (in dollars per share) | $ / shares	$ 3.58
Intrinsic value of options exercised | $	$ 145,053

Equity Incentive Plans, Options

Equity Incentive Plans, Options Outstanding and Vested and Currently Exercisable by Exercise Prices (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Option outstanding [Abstract]
Option outstanding, exercise price (in dollars per share)	$ 3.58	$ 3.60
Option outstanding, outstanding (in shares)	696,163	743,627
Option outstanding, weighted average remaining life years	5 years 7 months 17 days
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	507,969
Options vested and exercisable, Weighted average remaining life years	5 years 6 months 25 days
$1.71 [Member]
Option outstanding [Abstract]
Option outstanding, exercise price (in dollars per share)	$ 1.71
Option outstanding, outstanding (in shares)	227,780
Option outstanding, weighted average remaining life years	4 years 5 months 15 days
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	116,669
Options vested and exercisable, Exercise price (in dollars per share)	$ 1.71
Options vested and exercisable, Weighted average remaining life years	4 years 5 months 15 days
$3.24 [Member]
Option outstanding [Abstract]
Option outstanding, exercise price (in dollars per share)	$ 3.24
Option outstanding, outstanding (in shares)	284,282
Option outstanding, weighted average remaining life years	5 years 9 months
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	284,282
Options vested and exercisable, Exercise price (in dollars per share)	$ 3.24
Options vested and exercisable, Weighted average remaining life years	5 years 9 months
$3.96 [Member]
Option outstanding [Abstract]
Option outstanding, exercise price (in dollars per share)	$ 3.96
Option outstanding, outstanding (in shares)	67,422
Option outstanding, weighted average remaining life years	6 years 5 months 15 days
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	54,645
Options vested and exercisable, Exercise price (in dollars per share)	$ 3.96
Options vested and exercisable, Weighted average remaining life years	6 years 5 months 12 days
$4.50 [Member]
Option outstanding [Abstract]
Option outstanding, exercise price (in dollars per share)	$ 4.50
Option outstanding, outstanding (in shares)	1,667
Option outstanding, weighted average remaining life years	7 years 1 month 13 days
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	834
Options vested and exercisable, Exercise price (in dollars per share)	$ 4.50
Options vested and exercisable, Weighted average remaining life years	7 years 1 month 13 days
$4.95 [Member]
Option outstanding [Abstract]
Option outstanding, exercise price (in dollars per share)	$ 4.95
Option outstanding, outstanding (in shares)	44,445
Option outstanding, weighted average remaining life years	7 years 5 months 26 days
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	22,223
Options vested and exercisable, Exercise price (in dollars per share)	$ 4.95
Options vested and exercisable, Weighted average remaining life years	7 years 5 months 26 days
$6.12 [Member]
Option outstanding [Abstract]
Option outstanding, exercise price (in dollars per share)	$ 6.12
Option outstanding, outstanding (in shares)	58,342
Option outstanding, weighted average remaining life years	8 years 2 months 12 days
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	17,091
Options vested and exercisable, Exercise price (in dollars per share)	$ 6.12
Options vested and exercisable, Weighted average remaining life years	8 years 2 months 12 days
$27.00 [Member]
Option outstanding [Abstract]
Option outstanding, exercise price (in dollars per share)	$ 27
Option outstanding, outstanding (in shares)	12,225
Option outstanding, weighted average remaining life years	9 months 25 days
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	12,225
Options vested and exercisable, Exercise price (in dollars per share)	$ 27
Options vested and exercisable, Weighted average remaining life years	9 months 25 days

Equity Incentive Plans, Stock-B

Equity Incentive Plans, Stock-Based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock Based Compensation [Abstract]
Stock based compensation expense	$ 33,388	$ 80,771	$ 163,924	$ 239,075
Stock based compensation expense expected to be recognized for employees and nonemployees	320,193		320,193
Compensation expense to be recognized upon achieving certain performance condition			155,222
Unrecognized expenses	$ 164,971		$ 164,971
Weighted-average period over which unrecognized compensation is expected to be recognized			1 year 8 months 12 days

Equity Incentive Plans, Employe

Equity Incentive Plans, Employee Stock Purchase Plan ("ESPP") (Details) - 2021 Employee Stock Purchase Plan [Member]	9 Months Ended
	Sep. 30, 2021Datesshares
Employee Stock Purchase Plan [Abstract]
Common stock available for purchase (in shares)	166,666
Shares available for purchase under ESPP expressed as percentage of common stock outstanding	1.00%
Common stock outstanding (in shares)	222,222
Duration of purchase offering	27 months
Restriction for employees to purchase common stock under the ESPP (in shares)	12,254
Percentage of fair market value of common stock on last date and first day of offering period	85.00%
Common stock purchased (in shares)	0
Minimum [Member]
Employee Stock Purchase Plan [Abstract]
Number of purchase dates of offering | Dates	1

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net Loss per Share Attributable to Common Stockholders [Abstract]
Net loss attributable to common stockholders, basic	$ (2,259,701)	$ (1,568,295)	$ (5,172,992)	$ (5,255,473)
Net loss attributable to common stockholders, diluted	$ (2,259,701)	$ (1,568,295)	$ (5,172,992)	$ (5,255,473)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	11,799,720	955,649	4,996,680	955,402
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	11,799,720	955,649	4,996,680	955,402
Net loss per share attributable to common stockholders, basic (In dollars per share)	$ (0.19)	$ (1.64)	$ (1.04)	$ (5.50)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.19)	$ (1.64)	$ (1.04)	$ (5.50)
Weighted Average Number of Shares Outstanding [Abstract]
Convertible preferred stock outstanding (in shares)	0	8,116,343	0	8,116,343
Options to purchase common stock (in shares)	696,163	780,862	696,163	780,862
Warrants to purchase common stock (in shares)	244,572	244,572	244,572	244,572
Total potential shares (in shares)	940,735	9,141,777	940,735	9,141,777